Literature DB >> 31656764

Systemic therapy for metastatic renal cell carcinoma-is timing everything?

Ritesh R Kotecha1, Martin H Voss1,2.   

Abstract

Entities:  

Year:  2019        PMID: 31656764      PMCID: PMC6789351          DOI: 10.21037/atm.2019.07.46

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  17 in total

1.  The effect of a treatment delay on outcome in metastatic renal cell carcinoma.

Authors:  Roberto Iacovelli; Luca Galli; Ugo De Giorgi; Camillo Porta; Franco Nolè; Paolo Zucali; Roberto Sabbatini; Alessandra Mosca; Francesco Atzori; Daniele Santini; Gaetano Facchini; Giuseppe Fornarini; Sebastiano Buti; Francesco Massari; Cristina Masini; Riccardo Ricotta; Elisa Biasco; Cristian Lolli; Nicole Gri; Elena Verri; Chiara Miggiano; Maria Giuseppa Vitale; Giampaolo Tortora
Journal:  Urol Oncol       Date:  2019-03-29       Impact factor: 3.498

2.  Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials.

Authors:  A M Molina; X Lin; B Korytowsky; E Matczak; M J Lechuga; R Wiltshire; R J Motzer
Journal:  Eur J Cancer       Date:  2013-09-16       Impact factor: 9.162

3.  Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.

Authors:  Martin H Voss; Albert Reising; Yuan Cheng; Parul Patel; Mahtab Marker; Fengshen Kuo; Timothy A Chan; Toni K Choueiri; James J Hsieh; A Ari Hakimi; Robert J Motzer
Journal:  Lancet Oncol       Date:  2018-11-08       Impact factor: 41.316

4.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Authors:  Brian I Rini; Elizabeth R Plimack; Viktor Stus; Rustem Gafanov; Robert Hawkins; Dmitry Nosov; Frédéric Pouliot; Boris Alekseev; Denis Soulières; Bohuslav Melichar; Ihor Vynnychenko; Anna Kryzhanivska; Igor Bondarenko; Sergio J Azevedo; Delphine Borchiellini; Cezary Szczylik; Maurice Markus; Raymond S McDermott; Jens Bedke; Sophie Tartas; Yen-Hwa Chang; Satoshi Tamada; Qiong Shou; Rodolfo F Perini; Mei Chen; Michael B Atkins; Thomas Powles
Journal:  N Engl J Med       Date:  2019-02-16       Impact factor: 91.245

5.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Nizar M Tannir; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K Choueiri; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Victoria Neiman; Christian K Kollmannsberger; Pamela Salman; Howard Gurney; Robert Hawkins; Alain Ravaud; Marc-Oliver Grimm; Sergio Bracarda; Carlos H Barrios; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Allen C Chen; Sabeen Mekan; M Brent McHenry; Megan Wind-Rotolo; Justin Doan; Padmanee Sharma; Hans J Hammers; Bernard Escudier
Journal:  N Engl J Med       Date:  2018-03-21       Impact factor: 91.245

6.  Racial disparities in survival among patients with advanced renal cell carcinoma in the targeted therapy era.

Authors:  Tracy L Rose; Allison M Deal; Bhavani Krishnan; Matthew E Nielsen; Angela B Smith; William Y Kim; Matthew I Milowsky
Journal:  Cancer       Date:  2016-06-24       Impact factor: 6.860

7.  Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.

Authors:  Arnaud Méjean; Alain Ravaud; Simon Thezenas; Sandra Colas; Jean-Baptiste Beauval; Karim Bensalah; Lionnel Geoffrois; Antoine Thiery-Vuillemin; Luc Cormier; Hervé Lang; Laurent Guy; Gwenaelle Gravis; Frederic Rolland; Claude Linassier; Eric Lechevallier; Christian Beisland; Michael Aitchison; Stephane Oudard; Jean-Jacques Patard; Christine Theodore; Christine Chevreau; Brigitte Laguerre; Jacques Hubert; Marine Gross-Goupil; Jean-Christophe Bernhard; Laurence Albiges; Marc-Olivier Timsit; Thierry Lebret; Bernard Escudier
Journal:  N Engl J Med       Date:  2018-06-03       Impact factor: 91.245

8.  Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.

Authors:  Axel Bex; Peter Mulders; Michael Jewett; John Wagstaff; Johannes V van Thienen; Christian U Blank; Roland van Velthoven; Maria Del Pilar Laguna; Lori Wood; Harm H E van Melick; Maureen J Aarts; J B Lattouf; Thomas Powles; Igle Jan de Jong Md PhD; Sylvie Rottey; Bertrand Tombal; Sandrine Marreaud; Sandra Collette; Laurence Collette; John Haanen
Journal:  JAMA Oncol       Date:  2019-02-01       Impact factor: 31.777

9.  Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: role of inflammatory signaling.

Authors:  Lorenzo Cohen; Steven W Cole; Anil K Sood; Sarah Prinsloo; Clemens Kirschbaum; Jesusa M G Arevalo; Nicholas B Jennings; Shellie Scott; Luis Vence; Qi Wei; Diane Kentor; Laszlo Radvanyi; Nizar Tannir; Eric Jonasch; Pheroze Tamboli; Louis Pisters
Journal:  PLoS One       Date:  2012-08-01       Impact factor: 3.240

10.  Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial.

Authors:  Brian I Rini; Tanya B Dorff; Paul Elson; Cristina Suarez Rodriguez; Dale Shepard; Laura Wood; Jordi Humbert; Linda Pyle; Yu-Ning Wong; James H Finke; Patricia A Rayman; James M G Larkin; Jorge A Garcia; Elizabeth R Plimack
Journal:  Lancet Oncol       Date:  2016-08-03       Impact factor: 54.433

View more
  1 in total

1.  Comprehensive analysis on the expression levels and prognostic values of LOX family genes in kidney renal clear cell carcinoma.

Authors:  Shitong Lin; Lingling Zheng; Yuchao Lu; Qidong Xia; Peng Zhou; Zheng Liu
Journal:  Cancer Med       Date:  2020-09-24       Impact factor: 4.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.